Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The Provost Fellows Foundation Scholars And The Other Members Of Board Of The College Of The Holy maintains a highly concentrated patent portfolio within the Chemistry & Materials technology area. Currently, the company has 1 pending office action across its entire filing set. This single action is being handled by 1 distinct examiner, which indicates a very narrow and focused interaction with the patent office at this stage. The prosecution activity is confined to 1 distinct art unit, suggesting that the underlying technology is specialized.
SHAO, PHILLIP Y is identified as the busiest examiner for this portfolio. This individual is responsible for the 1 busiest examiner pending action, representing the entirety of the company's current workload. The alignment of 1 distinct examiner and 1 distinct art unit simplifies the logistical burden of monitoring multiple examiner behaviors or art unit trends. This concentration allows for a deep dive into the specific preferences and history of the 1 distinct examiner involved.
For practitioners, this data shows a singular point of contact within the patent office. The presence of 1 pending office action means that the prosecution strategy is currently focused on a single application or a very small group of related filings. The 1 distinct art unit also provides a stable procedural environment for the pending case. This focused approach is characteristic of portfolios with a single active case, allowing for maximum attention to the nuances of the pending action.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §102 only | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOEKSTRA, JEFFREY GERBEN | 1 | 56.1% | +39.8% |
| VAJDA, KRISTIN ANN | 1 | 83.8% | +11.1% |
| CREWS, JARET JAMES | 1 | 43.9% | +71.3% |
| PATEL, OM | 1 | 58.0% | +52.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18540743 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | VAJDA, KRISTIN ANN | 72d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039107 | IMMUNOTHERAPY FOR CANCER | CREWS, JARET JAMES | 16d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17271541 | OPTICAL DEVICE AND METHOD | PATEL, OM | 114d overdue |
| 18039107 | IMMUNOTHERAPY FOR CANCER | CREWS, JARET JAMES | 16d |
| 18540743 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | VAJDA, KRISTIN ANN | 72d |
| 18865301 | FINGER DEXTERITY DEVICE | HOEKSTRA, JEFFREY GERBEN | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1691 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18865301 | FINGER DEXTERITY DEVICE | HOEKSTRA, JEFFREY GERBEN | — | §102 | Non-Final OA | — | Pending | Nov 12, 2024 |
| 18540743 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | VAJDA, KRISTIN ANN | 1622 | §102Other | Final Rejection | 72d | Pending | Dec 14, 2023 |
| 18039107 | IMMUNOTHERAPY FOR CANCER | CREWS, JARET JAMES | 1691 | §102§103 | Final Rejection | 16d | Pending | May 26, 2023 |
| 17271541 | OPTICAL DEVICE AND METHOD | PATEL, OM | 3791 | §103 | Non-Final OA | 114d overdue | Pending | Feb 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Provost Fellows Foundation Scholars And The Other Members Of Board Of The College Of The Hol has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Jeffrey Gerben Hoekstra has the most, with 1 of The Provost Fellows Foundation Scholars And The Other Members Of Board Of The College Of The Hol's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
